Projet ANTIVIRALS (Horizon 2020, appel à projets 2014)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : CLOSED

Viral infections are a major cause of disease, mortality and economic losses worldwide. Antiviral therapy is an essential instrument to control virus infections. At present, however, licensed antiviral drugs have been developed only against a limited number of viruses (e.g. HIV, HCV, influenza, herpesviruses). There is a clear and unmet need for antiviral drugs to treat infections with other important human pathogens. Europe needs well-trained experts with multidisciplinary skills to advance the antiviral drug development field. However, few, if any, European universities or research institutes have the ability to deliver an intersectoral training programme that covers the broad spectrum of disciplines important for antiviral drug development. The ANTIVIRALS partnership has been established to fill this gap. It consists of six outstanding European academic partners and four industrial partners (two large R&D companies, of which one is specialized in antiviral drug discovery and development, and two SMEs), and two partner organisations (incl. one SME specialised in education). All partners are leaders in their field, ensuring state-of-the-art training possibilities, and their skills are highly complementary. ANTIVIRALS aims to introduce 15 ESRs to state-of-the-art knowledge and technology applied in antiviral drug development through both local and network-wide training activities. Individual research projects, research training workshops and intersectoral secondments will be supplemented with complementary skills courses and dissemination activities to improve career development and perspectives. The industrial partners are actively involved in the entire programme and will organize an industry-oriented conference aimed at further bridging the gap between academia and industry. Thus, ANTIVIRALS offers talented researchers a multidisciplinary and intersectoral training programme and prepares them for a future leading role in antiviral drug development in Europe.

Mots clés : antivirals, picornavirus, coronavirus, dengue, chikungunya virus, hepatitis b virus, small molecule inhibitors, alphabodies, structure based drug design, ligand based drug design

Participants :
- University Hospital Heidelberg (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 498432.96 €
- Virology Education (Pays-Bas) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- University of Vienna (Autriche) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 244061.58 €
- Utrecht University (Pays-Bas) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 510748.56 €
- Cardiff University (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 546575.76 €
- AiCuris (Germany) (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 249216.48 €
- Aratana therapeutics nv (Belgique) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 0.0 €
- Aix-Marseille Université (France) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 525751.2 €
- Leiden University Medical Center (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 510748.56 €
- Complix luxembourg sa (Luxembourg) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 99063.77 €
- KU Leuven (Belgique) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 402055.54 €
- Virovet (Belgique) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 250560.0 €
- Complix nv (Belgique) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 0.0 €